

The Future of U.S. Global Health Policy & Programs

Wednesday, January 20, 2016

9:30 a.m. – 11:00 a.m.

BIOGRAPHIES

Deborah L. Birx

Ambassador-at-Large, Deborah L. Birx, M.D., is the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy. Ambassador Birx is a world-renowned medical expert and leader in the field of HIV/AIDS. Her three-decade-long career has focused on HIV/AIDS immunology, vaccine research, and global health. As the U.S. Global AIDS Coordinator, Ambassador Birx oversees the implementation of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), the largest commitment by any nation to combat a single disease in history, as well as all U.S. Government engagement with the Global Fund to Fight AIDS, Tuberculosis and Malaria. Serving as the U.S. Special Representative for Global Health Diplomacy, she aligns the U.S. Government's diplomacy with foreign assistance programs that address global health challenges and accelerate progress toward: achieving an AIDS-free generation; ending preventable child and maternal deaths; and preventing, detecting, and responding to infectious disease threats.

In 1985, Ambassador Birx began her career with the Department of Defense (DoD) as a military-trained clinician in immunology, focusing on HIV/AIDS vaccine research. From 1985-1989, she served as an Assistant Chief of the Hospital Immunology Service at Walter Reed Army Medical Center. Through her professionalism and leadership in the field, she progressed to serve as the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research from 1996-2005. Ambassador Birx helped lead one of the most influential HIV vaccine trials in history (known as RV 144 or the Thai trial), which provided the first supporting evidence of any vaccine's potential effectiveness in preventing HIV infection. During this time, she also rose to the rank of Colonel, bringing together the Navy, Army, and Air Force in a new model of cooperation - increasing the efficiency and effectiveness of the U.S. Military's HIV/AIDS efforts through inter- and intra-agency collaboration. Then known as Colonel Birx, she was awarded two prestigious U.S. Meritorious Service Medals and the Legion of Merit Award for her groundbreaking research, leadership, and management skills during her tenure at DOD.

From 2005-2014, Ambassador Birx served successfully as the Director of CDC's Division of Global HIV/AIDS (DGHA), which is part of the agency's Center for Global Health. As DGHA Director, she utilized her leadership ability, superior technical skills, and infectious passion to achieve tremendous public health impact. She successfully led the implementation of CDC's PEPFAR programs around the world and managed an annual budget of more than \$1.5 billion. Ambassador Birx was responsible for all of the agency's global HIV/AIDS activities, including providing oversight to more than 400 staff at headquarters, over 1,500 staff in the field, and more than 45 country and regional offices in Africa, Asia, Caribbean, and Latin America. Recognized for her distinguished and dedicated commitment to building local capacity and strengthening quality laboratory health services and systems in Africa, in 2011, Ambassador Birx received a Lifetime Achievement Award from the African Society for Laboratory Medicine. In 2014, CDC honored her leadership in advancing the agency's HIV/AIDS response with the highly prestigious William C. Watson, Jr. Medal of Excellence.

Ambassador Birx has published over 220 manuscripts in peer-reviewed journals, authored nearly a dozen chapters in scientific publications, as well as developed and patented vaccines. She received her medical degree from the Hershey School of Medicine, Pennsylvania State University, and beginning in 1980 she trained in internal medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Ambassador Birx is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology.

Helene D. Gayle

Helene D. Gayle is CEO of McKinsey Social Initiative, a nonprofit organization that implements programs that bring together varied stakeholders to address complex global social challenges. Previously, she was president and CEO of CARE USA, a leading international humanitarian organization. An expert on global development, humanitarian, and health issues, she spent 20 years with the Centers for Disease Control, working primarily on HIV/AIDS. Dr. Gayle then worked at the Bill & Melinda Gates Foundation, directing programs on HIV/AIDS and other global health issues.

Dr. Gayle serves on public company and non-profit boards including: The Coca-Cola Company, Colgate-Palmolive Company, the Rockefeller Foundation, the Center for Strategic and International Studies, the New America Foundation, the ONE Campaign, and the Atlanta Metro Chamber of Commerce. Additionally, she serves on the President's Commission on White House Fellowships. She is a member of the Council on Foreign Relations, the American Public Health Association, the Institute of Medicine, and the American Academy of Pediatrics.

Named one of Forbes' "100 Most Powerful Women," she has authored numerous articles on global and domestic public health issues, poverty alleviation, gender equality, and social justice.

Dr. Gayle was born and raised in Buffalo, NY. She earned a B.A. in psychology at Barnard College, an M.D. from the University of Pennsylvania, and an M.P.H. from Johns Hopkins University. She has received 13 honorary degrees and holds faculty appointments at the University of Washington and Emory University.

Jen Kates

Dr. Jen Kates is Vice President and Director of Global Health & HIV Policy at the Kaiser Family Foundation, where she oversees the Foundation's policy analysis and research focused on the U.S. government's role in global health and on the global and domestic HIV epidemics. Widely regarded as an expert in the field, she regularly publishes and presents on global health and HIV policy issues and is particularly known for her work analyzing donor government investments in global health; assessing and mapping the U.S. government's global health architecture, programs, and funding; and tracking and analyzing major U.S. HIV programs and financing, and key trends in the HIV epidemic, an area she has been working in for twenty-five years. Prior to joining the Foundation in 1998, Dr. Kates was a Senior Associate with The Lewin Group, a health care consulting firm, where she focused on HIV policy, strategic planning/health systems analysis, and health care for vulnerable populations. Among other prior positions, she directed the Office of Lesbian, Gay, and Bisexual Concerns at Princeton University.

Dr. Kates serves on numerous federal and private sector advisory committees on global health and HIV issues. Currently, she is a member of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT), is an Alternate Board Member of the Global Fund to Fight AIDS, Tuberculosis and Malaria, and serves on PEPFAR's Scientific Advisory Board. She recently served on the Institute of Medicine's (IOM) Congressionally-mandated evaluation of PEPFAR, and on two IOM study committees commissioned by the White House to inform the implementation of the National HIV/AIDS Strategy.

Dr. Kates received her Ph.D. in Health Policy from George Washington University, where she is also a lecturer. She is also a lecturer at the Johns Hopkins School of Advanced International Studies. She holds a Bachelor's degree from Dartmouth College, a Master's degree in Public Affairs from Princeton University's Woodrow Wilson School of Public and International Affairs and a Master's degree in Political Science from the University of Massachusetts.

J. Stephen Morrison

J. Stephen Morrison is senior vice president at the Center for Strategic and International Studies (CSIS) and director of its Global Health Policy Center. Dr. Morrison writes widely, has directed several high-level commissions, and is a frequent commentator on U.S. foreign policy, global health, Africa, and foreign assistance. He served in the Clinton administration, as committee staff in the House of Representatives, and taught for 12 years at the Johns Hopkins School of Advanced International Studies. He holds a Ph.D. in political science from the University of Wisconsin and is a magna cum laude graduate of Yale College.

Tommy G. Thompson

Tommy G. Thompson currently is the Chairman and Chief Executive Officer of Thompson Holdings, and former United States Health and Human Services (HHS) Secretary and four-term Governor of Wisconsin. Following his term in public office, he built, and continues to build with his work at Thompson Holdings, on his efforts as HHS Secretary and Governor to develop innovative solutions to the health care challenges facing American families, businesses, communities, states and the nation as a whole. These efforts focus on improving the use of information technology in hospitals, clinics and doctors' offices; promoting healthier lifestyles; strengthening and modernizing Medicare and Medicaid; and expanding the use of medical diplomacy around the world. From 2005 until 2009, Governor Thompson served as a senior advisor at the consulting firm Deloitte LLP and was the founding independent chairman of the Deloitte Center for Health Solutions, which researches and develops solutions to some of our nation's most pressing health care and public health related challenges. From 2005 to early 2012, Governor Thompson served as a senior partner at the law firm of Akin, Gump, Strauss, Hauer, & Feld LLP. Governor Thompson served as Chairman of the Board of Directors of Logistics Health, Inc. from January 2011 to May 2011, and served as President from February 2005 to January 2011. He currently serves on the Board of Directors of the following public companies: Physicians Realty Trust and TherapeuticsMD, Inc., each as Chairman of the Board of Directors, Centene Corporation, C.R. Bard, Inc., Cytori Therapeutics, Inc. and United Therapeutics Corporation.